)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
AN2 Therapeutics
AN2 Therapeutics (ANTX) investor relations material
AN2 Therapeutics Status update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Status update summary4 Mar, 2026
Strategic rationale and market opportunity
Epetraborole is being advanced into polycythemia vera (PV) based on compelling data from non-PV patients, aiming to address a significant unmet need for oral, red cell-specific therapies.
The U.S. PV market is estimated at 150,000–155,000 patients, representing a substantial opportunity, with phase II trial initiation planned for Q3 2026 and initial data expected in Q4 2026, followed by updates through 2027.
Current PV treatments, including phlebotomy and cytoreductive agents, often fail to maintain hematocrit below 45%, highlighting the need for new options.
Durable hematocrit control is challenging with existing therapies, and no oral therapies specifically target erythrocytosis.
Clinical data and trial design
Epetraborole demonstrated consistent, dose-dependent, and reversible hematocrit reduction in phase I, II, and II/III studies, with minimal impact on white blood cells and platelets.
The phase II trial will include open-label and placebo-controlled cohorts, dose optimization, and an optional extension, focusing on phlebotomy-dependent PV patients.
Key objectives are to assess efficacy, optimize dosing, evaluate safety and tolerability, and measure patient-reported outcomes.
Real-time data will be collected on hematocrit control, pharmacokinetics, phlebotomy requirements, and safety, with enrollment of 40–50 patients across multiple sites.
Initial sentinel cohort data are expected in Q4 2026, with ongoing updates through 2027.
Mechanism of action and differentiation
Epetraborole is hypothesized to inhibit globin synthesis, selectively blocking red blood cell production at a specific marrow stage, with reversible effects and minimal risk of cytopenias.
Unlike current therapies, epetraborole is oral, red cell-specific, and does not significantly lower other blood counts, potentially reducing side effects and improving patient quality of life.
Once-daily oral administration and objective endpoints enable timely data readouts and flexible titration.
Elaborate on epetraborole's MOA differentiation
Identify the other two Phase 2 studies for 2026
How does epetraborole address current PV treatment gaps?
Epetraborole's MOA: How does it avoid cytopenias?
Quantify PV patients lacking hematocrit control.
What Sentinel cohort data informs go/no-go?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next AN2 Therapeutics earnings date
Leerink Global Healthcare Conference 202610 Mar, 2026
AN2 Therapeutics
Next AN2 Therapeutics earnings date
Leerink Global Healthcare Conference 202610 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
AN2 Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases. The company specializes in novel small-molecule therapies designed to address unmet medical needs, particularly in non-tuberculous mycobacterial (NTM) lung disease and other bacterial infections. The company is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage